Get the app
USHealthcare

Septerna, Inc. Common Stock (SEPN)

US · Healthcare · Biotechnology

$39.50+2.76%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$26.7M
Revenue YoY
+22375.6%
Net profit
$-13.0M
EPS
$-0.29
EPS estimate
$-0.48
Net margin
-48.7%

EPS came in at -0.29 against a street estimate of -0.48 — a beat of 39.6%.

Key statistics

Market cap
$1.80B
Forward P/E
107.5
P/B
4.65
Book value
$8.47
EPS (TTM)
$-0.53
52-week high
$51.10
52-week low
$14.35
50-day MA
$37.74
200-day MA
$29.99

Analyst view

Analysts rate Septerna, Inc. Common Stock a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $54.22.

Shareholding

Insiders
3.07%
Institutions
98.98%

Largest institutional holders

FundStake
RA Capital Management, LLC14.99%
TRV GP V, LLC13.32%
Driehaus Capital Management LLC9.42%
TRV GP VI, LLC9.02%
Samsara BioCapital, LLC6.75%
The Goldman Sachs Group Inc6.23%
Siren, L.L.C.4.28%
BlackRock Inc3.90%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 2026
SEPTERNA, INC. (SEPN) - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company appointed Rajiv Patni, M.D., as Chief Medical Officer effective August 2
2026-08-25
Quarterly report · Q2 2026
SEPTERNA, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and equivalents: $84.7 million (June 30, 2026) vs. $120.7 million (Dec 31, 2025) — dow
2026-08-10
Results announced · Q3 2026
SEPTERNA, INC. — Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $516.5 million in cash, cash equivalents, and marketable securities as
2026-08-10
Shareholder vote results · Q2 2026
SEPTERNA, INC. (NASDAQ: SEPN) – 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 26, 2026 • Total votes cast for Class II directo
2026-06-30
Quarterly report · Q1 2026
SEPTERNA, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and equivalents: $71.6 million as of March 31, 2026 (down from $120.7 million at Decem
2026-05-11
Results announced · Q2 2026
SEPTERNA, INC. — Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $522.1 million as of March 31, 2026 (down from $548.7 million at Decemb
2026-05-11
Proxy statement · Q2 2026
SEPTERNA, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class II directors to serve until the 2029 Ann
2026-04-30
Annual report FY2025
SEPTERNA, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Capitalization (as of June 30, 2025): $363.3 million (based on $10.57 p
2026-03-09

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Septerna, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.